IGC Pharma

We are a clinical stage pharmaceutical company, formerly known as India Globalization Capital, Inc.

About IGC Pharma (dba IGC):

IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with fast-acting, safe, and effective solutions. Our portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. The IGC-C and IGC-M platforms are advancing

in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov, NCT05543681). Clinical data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among others. With 28 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions.

05/31/2026

Caring for someone living with Alzheimer’s often means navigating uncertainty from day to day.

Establishing a consistent daily care plan can help create structure, reduce stress, and provide a greater sense of stability for both individuals and caregivers. Small adjustments, from timing activities thoughtfully to incorporating familiar routines, can make a meaningful difference.

Thoughtful planning supports more manageable, predictable days.

05/20/2026

On Clinical Trials Day, we recognize the role that structured, patient-centered research plays in advancing medicine.

Clinical trials rely on scientific rigor, regulatory responsibility, and the trust of the patients and investigators who make progress possible. Each study helps deepen our understanding of complex conditions such as Alzheimer’s disease and contributes to the development of more informed care approaches.

At IGC Pharma, our clinical development work is guided by integrity, transparency, and a commitment to responsible progress. Meaningful advancement requires not only innovation, but careful and disciplined ex*****on.

05/18/2026

New Tau-PET biomarker research by IGC Pharma was presented at the 2026 Global Tau Conference.

The poster, titled “Shannon Entropy of Tau-PET Spreading Patterns Predict Alzheimer’s Disease Progression in Amyloid-Positive APOE4 Carriers,” evaluated whether Shannon entropy can quantify spatial heterogeneity in tau pathology and may help predict future tau accumulation using data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI).

This work aligns with IGC Pharma’s broader strategy of integrating advanced analytics, neuroimaging, and AI-driven approaches to strengthen its Alzheimer’s research platform alongside the ongoing Phase 2 CALMA clinical trial.

Read the full press release: https://finance.yahoo.com/sectors/healthcare/articles/igc-pharma-present-tau-pet-120000503.html

05/13/2026

Alzheimer’s disease affects more than memory. It can influence how a person thinks, communicates, and responds to their surroundings over time.

For families and caregivers, these changes can be difficult to interpret. Understanding how Alzheimer’s impacts memory, cognition, and behavior provides important context for navigating daily life and care decisions.

Informed awareness supports more structured conversations and more thoughtful care planning.

05/07/2026

Music does more than move us, it engages the brain in powerful ways.

Researchers are exploring how musical memory networks function in Alzheimer’s disease, and why certain regions linked to music may remain relatively preserved even as the condition progresses.

By studying these neural connections, science continues to expand our understanding of how music-based interventions may support mood, behavior, and social engagement.

Learn more in our Science Spotlight: https://igcpharma.com/musical-memories-and-alzheimers-disease/

05/06/2026

Times Square marks more than a presence, it reflects another step in our journey.

Standing in the heart of New York is a reminder of the global scale of Alzheimer’s disease and the responsibility that comes with advancing research in this field.

As we continue progressing, each milestone represents new opportunities, higher standards, and a strengthened commitment to scientific excellence.

Scientific rigor and disciplined ex*****on remain at the core of our work as we focus on expanding the reach and impact of our research.

05/03/2026

Caregiving in Alzheimer’s disease can be deeply meaningful, and deeply demanding.

Support networks matter. Whether through shared experience, practical assistance, or simply having someone to talk to, connection plays an essential role in sustaining caregiver well-being.

Taking care of yourself is not separate from caregiving. It is part of it.

If you are supporting someone living with Alzheimer’s, know that resources and community can make a difference.

04/29/2026

As part of ongoing caregiver engagement efforts, IGC Pharma participated in the caregiver-focused podcast Autumn Is Here, featuring Margarita Venegas, Psychometric Training & Site Feasibility Manager, and Barbara Forero, Clinical Neuropsychologist & Recruitment Coordinator at IGC Pharma, in a discussion focused on recognizing agitation as a distinct and clinically significant symptom of Alzheimer’s disease.

The conversation was hosted by Francine Crawford, creator of Autumn Is Here, who brings a personal caregiving perspective. The outreach comes as the Phase 2 CALMA clinical trial advances toward enrollment completion (~80% enrolled).

Read the full press release: https://finance.yahoo.com/sectors/healthcare/articles/igc-pharma-advances-caregiver-engagement-161500157.html

Listen to the full episode: https://www.youtube.com/watch?v=uXguYFQb08I

04/23/2026

Kerwin Medical Center in Dallas, Texas has been added as a clinical site in IGC Pharma’s Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer’s disease, which has reached approximately 80% enrollment.

The site is led by Dr. Alka Khera, a behavioral neurologist with experience in Alzheimer’s clinical trials, supporting both patient recruitment and clinical ex*****on as the study progresses toward enrollment completion.

Read the full press release: https://finance.yahoo.com/sectors/healthcare/articles/igc-pharma-adds-kerwin-medical-123000687.html

04/21/2026

IGC Pharma has received authorization in Colombia to synthesize, formulate, and conduct development activities involving psilocybin at its research and development facility in Bogotá. This allows the Company to explore potential applications of psilocybin in neuropsychiatric symptoms (NPS) associated with dementia.

NPS affect approximately 80% of patients with Alzheimer’s disease and are broad and heterogeneous, including agitation, depression, anxiety, and mood-related conditions. While IGC-AD1 continues advancing through a Phase 2 clinical trial targeting agitation associated with Alzheimer’s disease, the Company believes that differentiated mechanisms may be required across these symptom clusters, creating the potential for multiple therapeutic pathways.

Read the full press release: https://finance.yahoo.com/sectors/healthcare/articles/igc-pharma-secures-psilocybin-research-123000764.html

Address

Potomac, MD

Telephone

+13019830998

Website

https://igcpharma.com/

Alerts

Be the first to know and let us send you an email when IGC Pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to IGC Pharma:

Shortcuts

Want your business to be the top-listed Health & Beauty Business in Potomac?